CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer
Molecular Carcinogenesis · 2026-07 · 65 (7) · 874-887
DOI: 10.1002/mc.70122 ↗At a glance
Journal article in Molecular Carcinogenesis, published online on 2026-04-26. Written by Shawn Noronha and 26 co-authors. Institution: Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA. Major MEDLINE topics: Proto-Oncogene Proteins B-raf, Thyroid Carcinoma, Anaplastic, Drug Resistance, Neoplasm, Thyroid Neoplasms. 59 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Anaplastic thyroid cancer (ATC) is the most aggressive form of thyroid cancer. Despite recent advances in treating BRAFV600E‐driven ATC, therapy resistance remains a significant challenge, often resulting in disease progression and death. Leveraging a focused CRISPR/KO screen in parallel with a CRISPR/activation screen, both tailored on response to BRAFV600E inhibitor treatment, we identified TAZ (encoded by WWTR1 gene) deficiency as synthetically lethal with BRAF inhibitor in ATC. TAZ is overexpressed in ATC compared to well‐differentiated thyroid tumors. We demonstrate that TAZ‐deficient ATC cells display heightened sensitivity to BRAF inhibitors. Using gene essentiality score across cancer cell lines, we found that BRAFV600E‐driven cancers are highly sensitive to TAZ loss, unlike their counterparts with wild‐type BRAF and non‐BRAFV600E. Mechanistically, we demonstrate that dabrafenib triggers the Unfolded Protein Response (UPR) under ER stress and suppresses protein synthesis. TAZ loss represses the UPR, reverses the inhibition of protein synthesis, and triggers increased cell death by ferroptosis in dabrafenib‐treated ATC. Collectively, our findings unveil TAZ as a new target to overcome resistance to BRAF inhibitors in undifferentiated thyroid cancer.
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Surgical Oncology Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
- Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
- Institute for Cellular and Molecular Biology, The University of Texas at Austin, Austin, Texas, USA.
- Laboratory Animal Sciences Program, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA.
- NCI Genomics Technology, Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research/Frederick, Maryland, USA.
- Collaborative Bioinformatics Resource, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
ORCID profiles: Maggie Cam, Jaydira Del Rivero, Myriem Boufraqech
Cite
APA
Noronha, S., Liu, Y., Geneti, G., Li, H., Wu, X., Sun, D., Gujar, V., Furusawa, T., Lobanov, A., Cam, M., Pal, L. R., Nair, N. U., Day, C. P., Ruppin, E., Ghosh, C., Hu, J., Ramamoorthy, B., Kumar, S., Andresson, T., …, & Boufraqech, M. (2026). CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer. Molecular Carcinogenesis, 65(7), 874-887. https://doi.org/10.1002/mc.70122
Vancouver
Noronha S, Liu Y, Geneti G, Li H, Wu X, Sun D, et al. CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer. Molecular Carcinogenesis. 2026;65(7):874-887. doi:10.1002/mc.70122
BibTeX
@article{Noronha2026,
author = {Noronha, Shawn and Liu, Yue and Geneti, Gaga and Li, Haojian and Wu, Xiaolin and Sun, David and Gujar, Vaibhavi and Furusawa, Takashi and Lobanov, Alexei and Cam, Maggie and Pal, Lipika R and Nair, Nishanth U and Day, Chi-Ping and Ruppin, Eytan and Ghosh, Chandrayee and Hu, Jiangnan and Ramamoorthy, Bhavishya and Kumar, Suresh and Andresson, Thorkell and Chan, King and O'Neill, Maura and Chari, Raj and Pommier, Yves and Rivero, Jaydira Del and Weyemi, Urbain and Kebebew, Electron and Boufraqech, Myriem},
title = {CRISPR‐Based Gene Dependency Screens Reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid Cancer},
journal = {Molecular Carcinogenesis},
year = {2026},
volume = {65},
number = {7},
pages = {874--887},
doi = {10.1002/mc.70122}
}
EUVIMED